Global Biologics for Tumors Market Research Report 2025

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Biologics for Tumors Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Monoclonal Antibodies
1.2.3 Recombinant Protein Drugs
1.2.4 Antibody-Drug Conjugates (ADCs)
1.2.5 Enzyme Replacement Therapy
1.2.6 CAR-T Drugs
1.2.7 Small Nucleic Acid Drugs
1.2.8 Others
1.3 Market by Properties
1.3.1 Global Biologics for Tumors Market Size Growth Rate by Properties: 2020 VS 2024 VS 2031
1.3.2 Biopharmaceuticals
1.3.3 Biosimilars
1.4 Market by Application
1.4.1 Global Biologics for Tumors Market Growth by Application: 2020 VS 2024 VS 2031
1.4.2 Lymphoma
1.4.3 Myeloma
1.4.4 Colorectal
1.4.5 Renal Cell Carcinoma
1.4.6 Others
1.5 Assumptions and Limitations
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Biologics for Tumors Market Perspective (2020-2031)
2.2 Global Biologics for Tumors Growth Trends by Region
2.2.1 Global Biologics for Tumors Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Biologics for Tumors Historic Market Size by Region (2020-2025)
2.2.3 Biologics for Tumors Forecasted Market Size by Region (2026-2031)
2.3 Biologics for Tumors Market Dynamics
2.3.1 Biologics for Tumors Industry Trends
2.3.2 Biologics for Tumors Market Drivers
2.3.3 Biologics for Tumors Market Challenges
2.3.4 Biologics for Tumors Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Biologics for Tumors Players by Revenue
3.1.1 Global Top Biologics for Tumors Players by Revenue (2020-2025)
3.1.2 Global Biologics for Tumors Revenue Market Share by Players (2020-2025)
3.2 Global Top Biologics for Tumors Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Biologics for Tumors Revenue
3.4 Global Biologics for Tumors Market Concentration Ratio
3.4.1 Global Biologics for Tumors Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biologics for Tumors Revenue in 2024
3.5 Global Key Players of Biologics for Tumors Head office and Area Served
3.6 Global Key Players of Biologics for Tumors, Product and Application
3.7 Global Key Players of Biologics for Tumors, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Biologics for Tumors Breakdown Data by Type
4.1 Global Biologics for Tumors Historic Market Size by Type (2020-2025)
4.2 Global Biologics for Tumors Forecasted Market Size by Type (2026-2031)
5 Biologics for Tumors Breakdown Data by Application
5.1 Global Biologics for Tumors Historic Market Size by Application (2020-2025)
5.2 Global Biologics for Tumors Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Biologics for Tumors Market Size (2020-2031)
6.2 North America Biologics for Tumors Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Biologics for Tumors Market Size by Country (2020-2025)
6.4 North America Biologics for Tumors Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Biologics for Tumors Market Size (2020-2031)
7.2 Europe Biologics for Tumors Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Biologics for Tumors Market Size by Country (2020-2025)
7.4 Europe Biologics for Tumors Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Biologics for Tumors Market Size (2020-2031)
8.2 Asia-Pacific Biologics for Tumors Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Biologics for Tumors Market Size by Region (2020-2025)
8.4 Asia-Pacific Biologics for Tumors Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Biologics for Tumors Market Size (2020-2031)
9.2 Latin America Biologics for Tumors Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Biologics for Tumors Market Size by Country (2020-2025)
9.4 Latin America Biologics for Tumors Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Biologics for Tumors Market Size (2020-2031)
10.2 Middle East & Africa Biologics for Tumors Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Biologics for Tumors Market Size by Country (2020-2025)
10.4 Middle East & Africa Biologics for Tumors Market Size by Country (2026-2031)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Biologics for Tumors Introduction
11.1.4 Roche Revenue in Biologics for Tumors Business (2020-2025)
11.1.5 Roche Recent Development
11.2 Merck
11.2.1 Merck Company Details
11.2.2 Merck Business Overview
11.2.3 Merck Biologics for Tumors Introduction
11.2.4 Merck Revenue in Biologics for Tumors Business (2020-2025)
11.2.5 Merck Recent Development
11.3 Novo Nordisk
11.3.1 Novo Nordisk Company Details
11.3.2 Novo Nordisk Business Overview
11.3.3 Novo Nordisk Biologics for Tumors Introduction
11.3.4 Novo Nordisk Revenue in Biologics for Tumors Business (2020-2025)
11.3.5 Novo Nordisk Recent Development
11.4 Sanofi
11.4.1 Sanofi Company Details
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Biologics for Tumors Introduction
11.4.4 Sanofi Revenue in Biologics for Tumors Business (2020-2025)
11.4.5 Sanofi Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Details
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Biologics for Tumors Introduction
11.5.4 Johnson & Johnson Revenue in Biologics for Tumors Business (2020-2025)
11.5.5 Johnson & Johnson Recent Development
11.6 AbbVie
11.6.1 AbbVie Company Details
11.6.2 AbbVie Business Overview
11.6.3 AbbVie Biologics for Tumors Introduction
11.6.4 AbbVie Revenue in Biologics for Tumors Business (2020-2025)
11.6.5 AbbVie Recent Development
11.7 Amgen
11.7.1 Amgen Company Details
11.7.2 Amgen Business Overview
11.7.3 Amgen Biologics for Tumors Introduction
11.7.4 Amgen Revenue in Biologics for Tumors Business (2020-2025)
11.7.5 Amgen Recent Development
11.8 AstraZeneca
11.8.1 AstraZeneca Company Details
11.8.2 AstraZeneca Business Overview
11.8.3 AstraZeneca Biologics for Tumors Introduction
11.8.4 AstraZeneca Revenue in Biologics for Tumors Business (2020-2025)
11.8.5 AstraZeneca Recent Development
11.9 Takeda Pharmaceuticals
11.9.1 Takeda Pharmaceuticals Company Details
11.9.2 Takeda Pharmaceuticals Business Overview
11.9.3 Takeda Pharmaceuticals Biologics for Tumors Introduction
11.9.4 Takeda Pharmaceuticals Revenue in Biologics for Tumors Business (2020-2025)
11.9.5 Takeda Pharmaceuticals Recent Development
11.10 Bristol-Myers Squib
11.10.1 Bristol-Myers Squib Company Details
11.10.2 Bristol-Myers Squib Business Overview
11.10.3 Bristol-Myers Squib Biologics for Tumors Introduction
11.10.4 Bristol-Myers Squib Revenue in Biologics for Tumors Business (2020-2025)
11.10.5 Bristol-Myers Squib Recent Development
11.11 Pfizer
11.11.1 Pfizer Company Details
11.11.2 Pfizer Business Overview
11.11.3 Pfizer Biologics for Tumors Introduction
11.11.4 Pfizer Revenue in Biologics for Tumors Business (2020-2025)
11.11.5 Pfizer Recent Development
11.12 Eli Lilly
11.12.1 Eli Lilly Company Details
11.12.2 Eli Lilly Business Overview
11.12.3 Eli Lilly Biologics for Tumors Introduction
11.12.4 Eli Lilly Revenue in Biologics for Tumors Business (2020-2025)
11.12.5 Eli Lilly Recent Development
11.13 Novartis
11.13.1 Novartis Company Details
11.13.2 Novartis Business Overview
11.13.3 Novartis Biologics for Tumors Introduction
11.13.4 Novartis Revenue in Biologics for Tumors Business (2020-2025)
11.13.5 Novartis Recent Development
11.14 GSK
11.14.1 GSK Company Details
11.14.2 GSK Business Overview
11.14.3 GSK Biologics for Tumors Introduction
11.14.4 GSK Revenue in Biologics for Tumors Business (2020-2025)
11.14.5 GSK Recent Development
11.15 CSL Limited
11.15.1 CSL Limited Company Details
11.15.2 CSL Limited Business Overview
11.15.3 CSL Limited Biologics for Tumors Introduction
11.15.4 CSL Limited Revenue in Biologics for Tumors Business (2020-2025)
11.15.5 CSL Limited Recent Development
11.16 Regeneron Pharmaceuticals
11.16.1 Regeneron Pharmaceuticals Company Details
11.16.2 Regeneron Pharmaceuticals Business Overview
11.16.3 Regeneron Pharmaceuticals Biologics for Tumors Introduction
11.16.4 Regeneron Pharmaceuticals Revenue in Biologics for Tumors Business (2020-2025)
11.16.5 Regeneron Pharmaceuticals Recent Development
11.17 Kexing Biopharm
11.17.1 Kexing Biopharm Company Details
11.17.2 Kexing Biopharm Business Overview
11.17.3 Kexing Biopharm Biologics for Tumors Introduction
11.17.4 Kexing Biopharm Revenue in Biologics for Tumors Business (2020-2025)
11.17.5 Kexing Biopharm Recent Development
11.18 Biogen
11.18.1 Biogen Company Details
11.18.2 Biogen Business Overview
11.18.3 Biogen Biologics for Tumors Introduction
11.18.4 Biogen Revenue in Biologics for Tumors Business (2020-2025)
11.18.5 Biogen Recent Development
11.19 GileadSciences
11.19.1 GileadSciences Company Details
11.19.2 GileadSciences Business Overview
11.19.3 GileadSciences Biologics for Tumors Introduction
11.19.4 GileadSciences Revenue in Biologics for Tumors Business (2020-2025)
11.19.5 GileadSciences Recent Development
11.20 Shanghai Junshi Biosciences
11.20.1 Shanghai Junshi Biosciences Company Details
11.20.2 Shanghai Junshi Biosciences Business Overview
11.20.3 Shanghai Junshi Biosciences Biologics for Tumors Introduction
11.20.4 Shanghai Junshi Biosciences Revenue in Biologics for Tumors Business (2020-2025)
11.20.5 Shanghai Junshi Biosciences Recent Development
11.21 Sarepta Therapeutics, Inc.
11.21.1 Sarepta Therapeutics, Inc. Company Details
11.21.2 Sarepta Therapeutics, Inc. Business Overview
11.21.3 Sarepta Therapeutics, Inc. Biologics for Tumors Introduction
11.21.4 Sarepta Therapeutics, Inc. Revenue in Biologics for Tumors Business (2020-2025)
11.21.5 Sarepta Therapeutics, Inc. Recent Development
11.22 Changchun High-Tech Industry
11.22.1 Changchun High-Tech Industry Company Details
11.22.2 Changchun High-Tech Industry Business Overview
11.22.3 Changchun High-Tech Industry Biologics for Tumors Introduction
11.22.4 Changchun High-Tech Industry Revenue in Biologics for Tumors Business (2020-2025)
11.22.5 Changchun High-Tech Industry Recent Development
11.23 Sino Biopharmaceutical Limited
11.23.1 Sino Biopharmaceutical Limited Company Details
11.23.2 Sino Biopharmaceutical Limited Business Overview
11.23.3 Sino Biopharmaceutical Limited Biologics for Tumors Introduction
11.23.4 Sino Biopharmaceutical Limited Revenue in Biologics for Tumors Business (2020-2025)
11.23.5 Sino Biopharmaceutical Limited Recent Development
11.24 Kexing Biopharm
11.24.1 Kexing Biopharm Company Details
11.24.2 Kexing Biopharm Business Overview
11.24.3 Kexing Biopharm Biologics for Tumors Introduction
11.24.4 Kexing Biopharm Revenue in Biologics for Tumors Business (2020-2025)
11.24.5 Kexing Biopharm Recent Development
11.25 3SBio Inc.
11.25.1 3SBio Inc. Company Details
11.25.2 3SBio Inc. Business Overview
11.25.3 3SBio Inc. Biologics for Tumors Introduction
11.25.4 3SBio Inc. Revenue in Biologics for Tumors Business (2020-2025)
11.25.5 3SBio Inc. Recent Development
11.26 CARsgen
11.26.1 CARsgen Company Details
11.26.2 CARsgen Business Overview
11.26.3 CARsgen Biologics for Tumors Introduction
11.26.4 CARsgen Revenue in Biologics for Tumors Business (2020-2025)
11.26.5 CARsgen Recent Development
11.27 Innovent Biologics
11.27.1 Innovent Biologics Company Details
11.27.2 Innovent Biologics Business Overview
11.27.3 Innovent Biologics Biologics for Tumors Introduction
11.27.4 Innovent Biologics Revenue in Biologics for Tumors Business (2020-2025)
11.27.5 Innovent Biologics Recent Development
11.28 Qilu Pharmaceutical
11.28.1 Qilu Pharmaceutical Company Details
11.28.2 Qilu Pharmaceutical Business Overview
11.28.3 Qilu Pharmaceutical Biologics for Tumors Introduction
11.28.4 Qilu Pharmaceutical Revenue in Biologics for Tumors Business (2020-2025)
11.28.5 Qilu Pharmaceutical Recent Development
11.29 Boehringer Ingelheim
11.29.1 Boehringer Ingelheim Company Details
11.29.2 Boehringer Ingelheim Business Overview
11.29.3 Boehringer Ingelheim Biologics for Tumors Introduction
11.29.4 Boehringer Ingelheim Revenue in Biologics for Tumors Business (2020-2025)
11.29.5 Boehringer Ingelheim Recent Development
11.30 BeiGene
11.30.1 BeiGene Company Details
11.30.2 BeiGene Business Overview
11.30.3 BeiGene Biologics for Tumors Introduction
11.30.4 BeiGene Revenue in Biologics for Tumors Business (2020-2025)
11.30.5 BeiGene Recent Development
11.31 Jiangsu Hengrui Pharmaceuticals
11.31.1 Jiangsu Hengrui Pharmaceuticals Company Details
11.31.2 Jiangsu Hengrui Pharmaceuticals Business Overview
11.31.3 Jiangsu Hengrui Pharmaceuticals Biologics for Tumors Introduction
11.31.4 Jiangsu Hengrui Pharmaceuticals Revenue in Biologics for Tumors Business (2020-2025)
11.31.5 Jiangsu Hengrui Pharmaceuticals Recent Development
11.32 Alphamab Oncology
11.32.1 Alphamab Oncology Company Details
11.32.2 Alphamab Oncology Business Overview
11.32.3 Alphamab Oncology Biologics for Tumors Introduction
11.32.4 Alphamab Oncology Revenue in Biologics for Tumors Business (2020-2025)
11.32.5 Alphamab Oncology Recent Development
11.33 Shanghai Henlius Biotech
11.33.1 Shanghai Henlius Biotech Company Details
11.33.2 Shanghai Henlius Biotech Business Overview
11.33.3 Shanghai Henlius Biotech Biologics for Tumors Introduction
11.33.4 Shanghai Henlius Biotech Revenue in Biologics for Tumors Business (2020-2025)
11.33.5 Shanghai Henlius Biotech Recent Development
11.34 Ionis Pharmaceuticals
11.34.1 Ionis Pharmaceuticals Company Details
11.34.2 Ionis Pharmaceuticals Business Overview
11.34.3 Ionis Pharmaceuticals Biologics for Tumors Introduction
11.34.4 Ionis Pharmaceuticals Revenue in Biologics for Tumors Business (2020-2025)
11.34.5 Ionis Pharmaceuticals Recent Development
11.35 Gan & Lee Pharmaceuticals
11.35.1 Gan & Lee Pharmaceuticals Company Details
11.35.2 Gan & Lee Pharmaceuticals Business Overview
11.35.3 Gan & Lee Pharmaceuticals Biologics for Tumors Introduction
11.35.4 Gan & Lee Pharmaceuticals Revenue in Biologics for Tumors Business (2020-2025)
11.35.5 Gan & Lee Pharmaceuticals Recent Development
11.36 Anhui Anke Biotechnology
11.36.1 Anhui Anke Biotechnology Company Details
11.36.2 Anhui Anke Biotechnology Business Overview
11.36.3 Anhui Anke Biotechnology Biologics for Tumors Introduction
11.36.4 Anhui Anke Biotechnology Revenue in Biologics for Tumors Business (2020-2025)
11.36.5 Anhui Anke Biotechnology Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

List of Tables
Table 1. Global Biologics for Tumors Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Monoclonal Antibodies
Table 3. Key Players of Recombinant Protein Drugs
Table 4. Key Players of Antibody-Drug Conjugates (ADCs)
Table 5. Key Players of Enzyme Replacement Therapy
Table 6. Key Players of CAR-T Drugs
Table 7. Key Players of Small Nucleic Acid Drugs
Table 8. Key Players of Others
Table 9. Global Biologics for Tumors Market Size Growth Rate by Properties (US$ Million): 2020 VS 2024 VS 2031
Table 10. Key Players of Biopharmaceuticals
Table 11. Key Players of Biosimilars
Table 12. Global Biologics for Tumors Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 13. Global Biologics for Tumors Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 14. Global Biologics for Tumors Market Size by Region (2020-2025) & (US$ Million)
Table 15. Global Biologics for Tumors Market Share by Region (2020-2025)
Table 16. Global Biologics for Tumors Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 17. Global Biologics for Tumors Market Share by Region (2026-2031)
Table 18. Biologics for Tumors Market Trends
Table 19. Biologics for Tumors Market Drivers
Table 20. Biologics for Tumors Market Challenges
Table 21. Biologics for Tumors Market Restraints
Table 22. Global Biologics for Tumors Revenue by Players (2020-2025) & (US$ Million)
Table 23. Global Biologics for Tumors Market Share by Players (2020-2025)
Table 24. Global Top Biologics for Tumors Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biologics for Tumors as of 2024)
Table 25. Ranking of Global Top Biologics for Tumors Companies by Revenue (US$ Million) in 2024
Table 26. Global 5 Largest Players Market Share by Biologics for Tumors Revenue (CR5 and HHI) & (2020-2025)
Table 27. Global Key Players of Biologics for Tumors, Headquarters and Area Served
Table 28. Global Key Players of Biologics for Tumors, Product and Application
Table 29. Global Key Players of Biologics for Tumors, Date of Enter into This Industry
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Biologics for Tumors Market Size by Type (2020-2025) & (US$ Million)
Table 32. Global Biologics for Tumors Revenue Market Share by Type (2020-2025)
Table 33. Global Biologics for Tumors Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 34. Global Biologics for Tumors Revenue Market Share by Type (2026-2031)
Table 35. Global Biologics for Tumors Market Size by Application (2020-2025) & (US$ Million)
Table 36. Global Biologics for Tumors Revenue Market Share by Application (2020-2025)
Table 37. Global Biologics for Tumors Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 38. Global Biologics for Tumors Revenue Market Share by Application (2026-2031)
Table 39. North America Biologics for Tumors Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 40. North America Biologics for Tumors Market Size by Country (2020-2025) & (US$ Million)
Table 41. North America Biologics for Tumors Market Size by Country (2026-2031) & (US$ Million)
Table 42. Europe Biologics for Tumors Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Europe Biologics for Tumors Market Size by Country (2020-2025) & (US$ Million)
Table 44. Europe Biologics for Tumors Market Size by Country (2026-2031) & (US$ Million)
Table 45. Asia-Pacific Biologics for Tumors Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 46. Asia-Pacific Biologics for Tumors Market Size by Region (2020-2025) & (US$ Million)
Table 47. Asia-Pacific Biologics for Tumors Market Size by Region (2026-2031) & (US$ Million)
Table 48. Latin America Biologics for Tumors Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 49. Latin America Biologics for Tumors Market Size by Country (2020-2025) & (US$ Million)
Table 50. Latin America Biologics for Tumors Market Size by Country (2026-2031) & (US$ Million)
Table 51. Middle East & Africa Biologics for Tumors Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 52. Middle East & Africa Biologics for Tumors Market Size by Country (2020-2025) & (US$ Million)
Table 53. Middle East & Africa Biologics for Tumors Market Size by Country (2026-2031) & (US$ Million)
Table 54. Roche Company Details
Table 55. Roche Business Overview
Table 56. Roche Biologics for Tumors Product
Table 57. Roche Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)
Table 58. Roche Recent Development
Table 59. Merck Company Details
Table 60. Merck Business Overview
Table 61. Merck Biologics for Tumors Product
Table 62. Merck Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)
Table 63. Merck Recent Development
Table 64. Novo Nordisk Company Details
Table 65. Novo Nordisk Business Overview
Table 66. Novo Nordisk Biologics for Tumors Product
Table 67. Novo Nordisk Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)
Table 68. Novo Nordisk Recent Development
Table 69. Sanofi Company Details
Table 70. Sanofi Business Overview
Table 71. Sanofi Biologics for Tumors Product
Table 72. Sanofi Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)
Table 73. Sanofi Recent Development
Table 74. Johnson & Johnson Company Details
Table 75. Johnson & Johnson Business Overview
Table 76. Johnson & Johnson Biologics for Tumors Product
Table 77. Johnson & Johnson Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)
Table 78. Johnson & Johnson Recent Development
Table 79. AbbVie Company Details
Table 80. AbbVie Business Overview
Table 81. AbbVie Biologics for Tumors Product
Table 82. AbbVie Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)
Table 83. AbbVie Recent Development
Table 84. Amgen Company Details
Table 85. Amgen Business Overview
Table 86. Amgen Biologics for Tumors Product
Table 87. Amgen Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)
Table 88. Amgen Recent Development
Table 89. AstraZeneca Company Details
Table 90. AstraZeneca Business Overview
Table 91. AstraZeneca Biologics for Tumors Product
Table 92. AstraZeneca Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)
Table 93. AstraZeneca Recent Development
Table 94. Takeda Pharmaceuticals Company Details
Table 95. Takeda Pharmaceuticals Business Overview
Table 96. Takeda Pharmaceuticals Biologics for Tumors Product
Table 97. Takeda Pharmaceuticals Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)
Table 98. Takeda Pharmaceuticals Recent Development
Table 99. Bristol-Myers Squib Company Details
Table 100. Bristol-Myers Squib Business Overview
Table 101. Bristol-Myers Squib Biologics for Tumors Product
Table 102. Bristol-Myers Squib Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)
Table 103. Bristol-Myers Squib Recent Development
Table 104. Pfizer Company Details
Table 105. Pfizer Business Overview
Table 106. Pfizer Biologics for Tumors Product
Table 107. Pfizer Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)
Table 108. Pfizer Recent Development
Table 109. Eli Lilly Company Details
Table 110. Eli Lilly Business Overview
Table 111. Eli Lilly Biologics for Tumors Product
Table 112. Eli Lilly Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)
Table 113. Eli Lilly Recent Development
Table 114. Novartis Company Details
Table 115. Novartis Business Overview
Table 116. Novartis Biologics for Tumors Product
Table 117. Novartis Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)
Table 118. Novartis Recent Development
Table 119. GSK Company Details
Table 120. GSK Business Overview
Table 121. GSK Biologics for Tumors Product
Table 122. GSK Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)
Table 123. GSK Recent Development
Table 124. CSL Limited Company Details
Table 125. CSL Limited Business Overview
Table 126. CSL Limited Biologics for Tumors Product
Table 127. CSL Limited Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)
Table 128. CSL Limited Recent Development
Table 129. Regeneron Pharmaceuticals Company Details
Table 130. Regeneron Pharmaceuticals Business Overview
Table 131. Regeneron Pharmaceuticals Biologics for Tumors Product
Table 132. Regeneron Pharmaceuticals Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)
Table 133. Regeneron Pharmaceuticals Recent Development
Table 134. Kexing Biopharm Company Details
Table 135. Kexing Biopharm Business Overview
Table 136. Kexing Biopharm Biologics for Tumors Product
Table 137. Kexing Biopharm Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)
Table 138. Kexing Biopharm Recent Development
Table 139. Biogen Company Details
Table 140. Biogen Business Overview
Table 141. Biogen Biologics for Tumors Product
Table 142. Biogen Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)
Table 143. Biogen Recent Development
Table 144. GileadSciences Company Details
Table 145. GileadSciences Business Overview
Table 146. GileadSciences Biologics for Tumors Product
Table 147. GileadSciences Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)
Table 148. GileadSciences Recent Development
Table 149. Shanghai Junshi Biosciences Company Details
Table 150. Shanghai Junshi Biosciences Business Overview
Table 151. Shanghai Junshi Biosciences Biologics for Tumors Product
Table 152. Shanghai Junshi Biosciences Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)
Table 153. Shanghai Junshi Biosciences Recent Development
Table 154. Sarepta Therapeutics, Inc. Company Details
Table 155. Sarepta Therapeutics, Inc. Business Overview
Table 156. Sarepta Therapeutics, Inc. Biologics for Tumors Product
Table 157. Sarepta Therapeutics, Inc. Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)
Table 158. Sarepta Therapeutics, Inc. Recent Development
Table 159. Changchun High-Tech Industry Company Details
Table 160. Changchun High-Tech Industry Business Overview
Table 161. Changchun High-Tech Industry Biologics for Tumors Product
Table 162. Changchun High-Tech Industry Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)
Table 163. Changchun High-Tech Industry Recent Development
Table 164. Sino Biopharmaceutical Limited Company Details
Table 165. Sino Biopharmaceutical Limited Business Overview
Table 166. Sino Biopharmaceutical Limited Biologics for Tumors Product
Table 167. Sino Biopharmaceutical Limited Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)
Table 168. Sino Biopharmaceutical Limited Recent Development
Table 169. Kexing Biopharm Company Details
Table 170. Kexing Biopharm Business Overview
Table 171. Kexing Biopharm Biologics for Tumors Product
Table 172. Kexing Biopharm Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)
Table 173. Kexing Biopharm Recent Development
Table 174. 3SBio Inc. Company Details
Table 175. 3SBio Inc. Business Overview
Table 176. 3SBio Inc. Biologics for Tumors Product
Table 177. 3SBio Inc. Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)
Table 178. 3SBio Inc. Recent Development
Table 179. CARsgen Company Details
Table 180. CARsgen Business Overview
Table 181. CARsgen Biologics for Tumors Product
Table 182. CARsgen Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)
Table 183. CARsgen Recent Development
Table 184. Innovent Biologics Company Details
Table 185. Innovent Biologics Business Overview
Table 186. Innovent Biologics Biologics for Tumors Product
Table 187. Innovent Biologics Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)
Table 188. Innovent Biologics Recent Development
Table 189. Qilu Pharmaceutical Company Details
Table 190. Qilu Pharmaceutical Business Overview
Table 191. Qilu Pharmaceutical Biologics for Tumors Product
Table 192. Qilu Pharmaceutical Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)
Table 193. Qilu Pharmaceutical Recent Development
Table 194. Boehringer Ingelheim Company Details
Table 195. Boehringer Ingelheim Business Overview
Table 196. Boehringer Ingelheim Biologics for Tumors Product
Table 197. Boehringer Ingelheim Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)
Table 198. Boehringer Ingelheim Recent Development
Table 199. BeiGene Company Details
Table 200. BeiGene Business Overview
Table 201. BeiGene Biologics for Tumors Product
Table 202. BeiGene Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)
Table 203. BeiGene Recent Development
Table 204. Jiangsu Hengrui Pharmaceuticals Company Details
Table 205. Jiangsu Hengrui Pharmaceuticals Business Overview
Table 206. Jiangsu Hengrui Pharmaceuticals Biologics for Tumors Product
Table 207. Jiangsu Hengrui Pharmaceuticals Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)
Table 208. Jiangsu Hengrui Pharmaceuticals Recent Development
Table 209. Alphamab Oncology Company Details
Table 210. Alphamab Oncology Business Overview
Table 211. Alphamab Oncology Biologics for Tumors Product
Table 212. Alphamab Oncology Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)
Table 213. Alphamab Oncology Recent Development
Table 214. Shanghai Henlius Biotech Company Details
Table 215. Shanghai Henlius Biotech Business Overview
Table 216. Shanghai Henlius Biotech Biologics for Tumors Product
Table 217. Shanghai Henlius Biotech Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)
Table 218. Shanghai Henlius Biotech Recent Development
Table 219. Ionis Pharmaceuticals Company Details
Table 220. Ionis Pharmaceuticals Business Overview
Table 221. Ionis Pharmaceuticals Biologics for Tumors Product
Table 222. Ionis Pharmaceuticals Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)
Table 223. Ionis Pharmaceuticals Recent Development
Table 224. Gan & Lee Pharmaceuticals Company Details
Table 225. Gan & Lee Pharmaceuticals Business Overview
Table 226. Gan & Lee Pharmaceuticals Biologics for Tumors Product
Table 227. Gan & Lee Pharmaceuticals Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)
Table 228. Gan & Lee Pharmaceuticals Recent Development
Table 229. Anhui Anke Biotechnology Company Details
Table 230. Anhui Anke Biotechnology Business Overview
Table 231. Anhui Anke Biotechnology Biologics for Tumors Product
Table 232. Anhui Anke Biotechnology Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)
Table 233. Anhui Anke Biotechnology Recent Development
Table 234. Research Programs/Design for This Report
Table 235. Key Data Information from Secondary Sources
Table 236. Key Data Information from Primary Sources
Table 237. Authors List of This Report


List of Figures
Figure 1. Biologics for Tumors Picture
Figure 2. Global Biologics for Tumors Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Biologics for Tumors Market Share by Type: 2024 VS 2031
Figure 4. Monoclonal Antibodies Features
Figure 5. Recombinant Protein Drugs Features
Figure 6. Antibody-Drug Conjugates (ADCs) Features
Figure 7. Enzyme Replacement Therapy Features
Figure 8. CAR-T Drugs Features
Figure 9. Small Nucleic Acid Drugs Features
Figure 10. Others Features
Figure 11. Global Biologics for Tumors Market Size Comparison by Properties (2020-2031) & (US$ Million)
Figure 12. Biopharmaceuticals Features
Figure 13. Biosimilars Features
Figure 14. Global Biologics for Tumors Market Size by Application (2020-2031) & (US$ Million)
Figure 15. Global Biologics for Tumors Market Share by Application: 2024 VS 2031
Figure 16. Lymphoma Case Studies
Figure 17. Myeloma Case Studies
Figure 18. Colorectal Case Studies
Figure 19. Renal Cell Carcinoma Case Studies
Figure 20. Others Case Studies
Figure 21. Biologics for Tumors Report Years Considered
Figure 22. Global Biologics for Tumors Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 23. Global Biologics for Tumors Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 24. Global Biologics for Tumors Market Share by Region: 2024 VS 2031
Figure 25. Global Biologics for Tumors Market Share by Players in 2024
Figure 26. Global Biologics for Tumors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 27. The Top 10 and 5 Players Market Share by Biologics for Tumors Revenue in 2024
Figure 28. North America Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. North America Biologics for Tumors Market Share by Country (2020-2031)
Figure 30. United States Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Canada Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Europe Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Europe Biologics for Tumors Market Share by Country (2020-2031)
Figure 34. Germany Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. France Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. U.K. Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Italy Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Russia Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Ireland Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Asia-Pacific Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Asia-Pacific Biologics for Tumors Market Share by Region (2020-2031)
Figure 42. China Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Japan Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. South Korea Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Southeast Asia Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. India Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Australia & New Zealand Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Latin America Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Latin America Biologics for Tumors Market Share by Country (2020-2031)
Figure 50. Mexico Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Brazil Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. Middle East & Africa Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 53. Middle East & Africa Biologics for Tumors Market Share by Country (2020-2031)
Figure 54. Israel Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 55. Saudi Arabia Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 56. UAE Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 57. Roche Revenue Growth Rate in Biologics for Tumors Business (2020-2025)
Figure 58. Merck Revenue Growth Rate in Biologics for Tumors Business (2020-2025)
Figure 59. Novo Nordisk Revenue Growth Rate in Biologics for Tumors Business (2020-2025)
Figure 60. Sanofi Revenue Growth Rate in Biologics for Tumors Business (2020-2025)
Figure 61. Johnson & Johnson Revenue Growth Rate in Biologics for Tumors Business (2020-2025)
Figure 62. AbbVie Revenue Growth Rate in Biologics for Tumors Business (2020-2025)
Figure 63. Amgen Revenue Growth Rate in Biologics for Tumors Business (2020-2025)
Figure 64. AstraZeneca Revenue Growth Rate in Biologics for Tumors Business (2020-2025)
Figure 65. Takeda Pharmaceuticals Revenue Growth Rate in Biologics for Tumors Business (2020-2025)
Figure 66. Bristol-Myers Squib Revenue Growth Rate in Biologics for Tumors Business (2020-2025)
Figure 67. Pfizer Revenue Growth Rate in Biologics for Tumors Business (2020-2025)
Figure 68. Eli Lilly Revenue Growth Rate in Biologics for Tumors Business (2020-2025)
Figure 69. Novartis Revenue Growth Rate in Biologics for Tumors Business (2020-2025)
Figure 70. GSK Revenue Growth Rate in Biologics for Tumors Business (2020-2025)
Figure 71. CSL Limited Revenue Growth Rate in Biologics for Tumors Business (2020-2025)
Figure 72. Regeneron Pharmaceuticals Revenue Growth Rate in Biologics for Tumors Business (2020-2025)
Figure 73. Kexing Biopharm Revenue Growth Rate in Biologics for Tumors Business (2020-2025)
Figure 74. Biogen Revenue Growth Rate in Biologics for Tumors Business (2020-2025)
Figure 75. GileadSciences Revenue Growth Rate in Biologics for Tumors Business (2020-2025)
Figure 76. Shanghai Junshi Biosciences Revenue Growth Rate in Biologics for Tumors Business (2020-2025)
Figure 77. Sarepta Therapeutics, Inc. Revenue Growth Rate in Biologics for Tumors Business (2020-2025)
Figure 78. Changchun High-Tech Industry Revenue Growth Rate in Biologics for Tumors Business (2020-2025)
Figure 79. Sino Biopharmaceutical Limited Revenue Growth Rate in Biologics for Tumors Business (2020-2025)
Figure 80. Kexing Biopharm Revenue Growth Rate in Biologics for Tumors Business (2020-2025)
Figure 81. 3SBio Inc. Revenue Growth Rate in Biologics for Tumors Business (2020-2025)
Figure 82. CARsgen Revenue Growth Rate in Biologics for Tumors Business (2020-2025)
Figure 83. Innovent Biologics Revenue Growth Rate in Biologics for Tumors Business (2020-2025)
Figure 84. Qilu Pharmaceutical Revenue Growth Rate in Biologics for Tumors Business (2020-2025)
Figure 85. Boehringer Ingelheim Revenue Growth Rate in Biologics for Tumors Business (2020-2025)
Figure 86. BeiGene Revenue Growth Rate in Biologics for Tumors Business (2020-2025)
Figure 87. Jiangsu Hengrui Pharmaceuticals Revenue Growth Rate in Biologics for Tumors Business (2020-2025)
Figure 88. Alphamab Oncology Revenue Growth Rate in Biologics for Tumors Business (2020-2025)
Figure 89. Shanghai Henlius Biotech Revenue Growth Rate in Biologics for Tumors Business (2020-2025)
Figure 90. Ionis Pharmaceuticals Revenue Growth Rate in Biologics for Tumors Business (2020-2025)
Figure 91. Gan & Lee Pharmaceuticals Revenue Growth Rate in Biologics for Tumors Business (2020-2025)
Figure 92. Anhui Anke Biotechnology Revenue Growth Rate in Biologics for Tumors Business (2020-2025)
Figure 93. Bottom-up and Top-down Approaches for This Report
Figure 94. Data Triangulation
Figure 95. Key Executives Interviewed

Your Name

Your E-mail

Your message

Submit